The Competition Commission of South Africa has initiated another important complaint involving TB drugs
top of page
![Test Tubes](https://static.wixstatic.com/media/dcc8233aaa7047df8139d146d9bbff35.jpg/v1/fill/w_224,h_149,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/dcc8233aaa7047df8139d146d9bbff35.jpg)
Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
JOIN THE MOVEMENT!
Get the Latest News & Updates
bottom of page